@article{APS6658,
author = {Guo-ping Yang and Hong Yuan and Bin Tang and Wei Zhang and Lian-sheng Wang and Zhi-jun Huang and Dong-sheng Ou-Yang and Gui-xiang Zhang and Hong-hao Zhou},
title = {Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients},
journal = {Acta Pharmacologica Sinica},
volume = {31},
number = {3},
year = {2016},
keywords = {},
abstract = {Aim: To investigate the SLCO1B1 388A>G and 521T>Cpolymorphisms in hyperlipidemia patients and evaluate the effect of the two polymorphisms on the lipid-lowering efficacy of pitavastatin.
Methods: The functional polymorphisms of SLCO1B1 (388A>G and 521T>C) were genotyped in 140 Chinese patients with essential hyperlipidemia using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and one-step tetra-primers ARMS-PCR. Eighty-five patients were enrolled in the clinical trial and given 2 mg of pitavastatin daily for 8 weeks. Total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) serum levels were measured at baseline, after 4 weeks and after 8 weeks of treatment.
Results: The allele frequencies of SLCO1B1 388A>G and 521T>C in essential hyperlipidemia patients were 71.1% and 11.1%, respectively. The 4- and 8-week treatment with pitavastatin significantly reduced TC, TG, and LDL levels, but there was no statistical difference among patients with wild type, SLCO1B1 388A>Gor SLCO1B1 521T>C in the lipid-lowering efficacy of pitavastatin.
Conclusion: The present study found that the allele frequencies of SLCO1B1388A>G and 521T>C in Chinese patients with essential hyperlipidemia are comparable to those in healthy Chinese population. SLCO1B1 388A>G and 521T>C do not affect the lipid-lowering efficacy of pitavastatin.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/6658}
}